Friday, January 19, 2007

Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain





Safe and Well Tolerated with No Serious Adverse Effects

ISELIN, N.J., January 19, 2007 /PRNewswire-FirstCall/ -. Pharmos Corp. today announced preliminary results from its Phase 2a study evaluating intravenous (i.v.) cannabinor, a CB2-selective synthetic cannabinoid compound, in a capsaicin-induced pain model. The drug candidate did not meet the primary endpoint defined by analgesic effects compared to placebo, but confirmed safety and tolerability observed in previous studies. All subjects completed the treatment with no serious adverse events or significant cardiovascular effects.


The randomized, double-blinded, two-way crossover study enrolled 24 healthy male volunteers to compare 48mg of cannabinor delivered intravenously versus placebo on capsaicin-evoked allodynia (pain resulting from a non- noxious stimulus to the skin) and hyperalgesia (abnormally increased pain sense).

"While we are disappointed that cannabinor did not show efficacy in this pain model, we have a newly developed oral formulation of cannabinor targeting chronic neuropathic pain with repeated administration," said Dr. Haim Aviv, Chairman & CEO. "We plan to move forward with the program for orally administered cannabinor, and our next step is to conduct a Phase I safety trial in healthy volunteers. Based on preclinical results of oral cannabinor, its prospects as a potential treatment for neuropathic pain are promising." Pharmos recently completed preclinical toxicology and safety pharmacology studies of oral cannabinor, the data from which support initiation of Phase 1 testing.

The Company expects to complete its separate, ongoing Phase 2a clinical trial of cannabinor as a treatment for nociceptive pain in the first quarter of 2007. The single-center, randomized, double-blinded, single-administration study compares different i.v. doses of cannabinor with placebo. The completed study will involve 100 healthy male subjects experiencing pain following third molar dental extraction.

About Cannabinor and CB2-Selective Cannabinoids

Cannabinor has demonstrated efficacy in a number of preclinical animal models of pain, inflammation and autoimmune disease. Analgesic activity has been documented in nociceptive, neuropathic, visceral and inflammatory pain in rodents and in post-operative pain in a porcine surgery model. The magnitude of analgesia was generally equivalent or greater than that of accepted comparator agents, including morphine, non-steroidal anti-inflammatory drugs and Gabapentin. In a number of models where duration of analgesia was measured, cannabinor remained effective at reducing pain significantly longer than morphine. Preliminary evidence from preclinical studies also suggests that tolerance to the therapeutic effect of cannabinor might not occur. A drug that remains effective without increasing dosage would be a valuable advance in treating severe pain.

Pharmos' cannabinoid research focus has been geared toward the development of selective and specific CB2 receptor agonists. Because they range from having little (CB2-selective) to barely detectable (CB2-specific) affinity for the central nervous system-located CB1 receptor, CB2-selective and -specific agonists lack the unwanted psychotropic side effects of many natural cannabinoids. CB2 agonists bind to CB2 receptors, which are located on immune and inflammatory cells. By activating CB2 receptors, CB2 agonists inhibit autoimmune and inflammatory processes, and are likely to be useful for treating pain, autoimmune, inflammatory and degenerative disorders. Pharmos is developing its CB2 agonists as treatments for chronic pain and autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis. Cannabinor is the first lead candidate to emerge from this body of Pharmos' proprietary technology.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications with a focus on specific diseases of the nervous system including disorders of the brain-gut axis (gastrointestinal/irritable bowel syndrome (IBS)), pain/inflammation, and autoimmune disorders. The Company's lead product, dextofisopam, has completed Phase 2a testing in IBS, with positive effect on the primary efficacy endpoint (n=141, p=0.033). The Company plans a Phase 2b study of dextofisopam for the treatment of IBS in 2007. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor and other CB2 agonist compounds in Pharmos' pipeline are in clinical and pre-clinical studies targeting pain, multiple sclerosis, rheumatoid arthritis and other disorders. Pharmos is also working to commercialize its unique proprietary NanoEmulsion drug delivery system, which is in clinical stage development for topical application of analgesic and anti-inflammatory agents.

CONTACT: Colin Neill, CFO, or Gale Smith, IR, both of Pharmos U.S.,+1-732-452-9556; or Irit Kopelov, Pharmos Israel, +972-8-940-9679; or JohnQuirk, investors, +1-646-536-7029, or Janine McCargo, media,+1-646-536-7033, both of The Ruth Group, Inc.

Web site: http://www.pharmoscorp.com/

Ticker Symbol: (NASDAQ-NMS:PARS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases





BERLIN, Jan. 19, 2007-Bayer Schering Pharma AG has signed a license and option agreement with Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd., and the National Institute of Radiological Sciences (NIRS), Japan, to develop novel imaging compounds for thedetection of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and other disorders also associated with neuroinflammation such as multiple sclerosis.

“We are convinced that innovations in molecular imaging have the potential to fundamentally improve the diagnosis of neurodegenerative disorders, particularly Alzheimer’s disease. Bayer Schering Pharma is already pursuing the development of tracers targeting amyloid plaques, a hallmark of this disease. Imaging of neuroinflammation as another important pathology will excellently complement these activities,” said Dr. Hans Maier, Head of Business Unit Diagnostic Imaging at Bayer Schering Pharma. “This agreement underscores our commitment to Alzheimer patients by developing innovative diagnostic methods for the early detection of the disease.”

Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd. and the National Institute of Radiological Sciences (NIRS) jointly own patent rights for a compound class that may be applied for various non-invasive imaging technologies, such as positron emission tomography (PET) scanning. Under the terms of the agreement Bayer Schering Pharma receives worldwide exclusive rights to develop and market therespective products for use with PET scanning technology.

Worldwide representative epidemiological surveys* estimate that 24.3 million people suffer from dementia today with about 4.6 million new cases occurring every year.

The number of people affected will double every 20 years to an estimated 81.1 million by 2040. Of these cases 50% to 75 % are associated with Alzheimer’s disease.

* Ferri C.P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366:2112-17

Bayer Schering Pharma AG is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology, Primary Care, and Oncology. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.

Additional Information

About Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Co., Ltd. is the leading non-prescription pharmaceutical company in Japan and has also been strengthening its research and development efforts in the area of prescription drugs. Taisho continues efforts to strengthen its prescription drug business through expansion of its novel original R&D and active collaboration with domestic and foreign pharmaceutical companies.

About Nihon Nohyaku Co., Ltd.,
Nihon Nohyaku Co., Ltd. is an agrochemical company listed on the Tokyo Stock exchange. Its core business is crop protection.

About the National Institute of Radiological Sciences (NIRS) The National Institute of Radiological Sciences (NIRS) in Japan is a state-owned research institution.

Your Contacts:
Oliver Renner, Tel. +49 30 468 12431
E-Mail: oliver.renner@schering.de
Dr. Claudia Schmitt, Tel: +49-30 468 15805
E-Mail: claudia.schmitt@schering.de

Important information from Bayer Schering Pharma AG:
Bayer Schering Pharma Aktiengesellschaft (formerly Schering Aktiengesellschaft) has filed a solicitation/recommendation statement with the U.S. Securities and Exchange Commission with respect to the offer of cash compensation by Bayer Schering GmbH (formerly Dritte BV GmbH), a wholly owned subsidiary of Bayer Aktiengesellschaft, in connection with the domination and profit and loss transfer agreement between Bayer Schering GmbH and Bayer Schering Pharma Aktiengesellschaft. Holders of ordinary shares and American depositary shares of Bayer Schering Pharma Aktiengesellschaft are advised to read such solicitation/recommendation statement because it contains important information. Holders of ordinary shares and American depositary shares of Bayer Schering Pharma Aktiengesellschaft may obtain such solicitation/recommendation statement and other filed documents free of charge at the U.S. Securities and Exchange Commission's website (http://www.sec.gov) and at Bayer Schering Pharma Aktiengesellschaft's website (http://www.schering.de).

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Bayer Schering Pharma AG’s plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Bayer Schering Pharma AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Thursday, January 18, 2007

An invitation-only stem cell summit is taking place in San Francisco this week, with the world's top scientists gathered to discuss the promise of ste





Jan. 17 - KGO

Dr. Douglas Kerr is a neurologist at Johns Hopkins. He led a team of scientists there, turning embryonic stem cells of mice into motor neurons in rats, allowing paralyzed rats to walk again by reconnecting the spinal cord with muscle. It's the kind of stem cell research being shared at this summit in San Francisco.

Douglas Kerr, M.D., Ph.D., Johns Hopkins, Dept. of Neurology: "There are stem cell biologists, and we have meetings, but you never interact with clinicians, people who think about changing this into a clinical trial or a clinical therapy."

John Richert, M.D., National MS Society, VP Research: "The field has come along to a point where many things that we thought were science fiction just a few years ago, now look like they may well be doable."

That's why the National Multiple Sclerosis Society is hosting this summit, bringing together world renowned researchers to help strategize how to move stem cell therapy forward in the treatment of MS.

Dr. Hans Keirstead: "I think we're going to see a consensus view that oligodendrocytes and glea that are made from human embryonic stem cells and other stem cell types are extremely useful for drug development and basic research."

The spinal cord research of Dr. Hans Keirstead and his team at UCI is expected to lead to the first clinical trial in North America using embryonic stem cells.

Dr. Hans Keirstead: "We take human embryonic stem cells, push them to become high purity populations of one spinal cord cell type, an oligodendrocyte."

Right now, he's successfully implanted those cells in paralyzed rats.

Dr. Hans Keirstead: "What happens is the insulators are restored and the ability of the animals to walk again is also restored."

Scientists will be sharing data and research for the next two days. On Friday they'll meet in groups to hammer out some specific recommendations for the MS Society, helping nail down how stem cell research could eventually help repair the nervous system or immune system of MS patients.

Related Link: http://www.nationalmssociety.org/promise2010.asp


Copyright 2007, ABC7/KGO-TV/DT

Agents raid medical marijuana advocacy office





Plants, computers and cash seized in Everett

By CASEY MCNERTHNEY AND CLAUDIA ROWE
P-I REPORTERS

Drug enforcement agents raided the Everett headquarters of an advocacy group for medical marijuana patients, confiscating what police documents say was more than 1,000 plants and computers that the owners say contain personal information of about 200 men and women authorized to use the drug for medicinal purposes.

So far, no one has been arrested or charged with a crime.

Fearful of potential repercussions and unsure of the officers' ultimate aim, patients in the CannaCare network of marijuana users have been "laying low," said one, terrified that they may be prosecuted for using a substance authorized by their physicians.

"Who knows what they're doing with our information?" said Steve Newman, who has multiple sclerosis and has been using marijuana, obtained through CannaCare, for two years. "It makes me concerned -- really, really concerned. But we're pretty helpless. Nobody can say much about it."

A detective assigned to the federally funded West Sound Narcotics Enforcement Team, which launched Friday's raid, scoffed at the notion that CannaCare -- run out of the home of medical marijuana advocate Steve Sarich -- was anything other than a drug-dealing enterprise.

Detective Roy Alloway said it was "absurd" to think that the number of plants Sarich was tending would be covered by his medical authorization.

"It's clear that Sarich is a guy that's selling drugs," said Alloway, who noted that state law allows no more than a 60-day supply of marijuana for medical use.

The amount found in Sarich's home, he said, was "not even close."

Long a thorn in the side of law enforcement for his vocal, thumb-in-the-eye advocacy style, Sarich, 56, insists that the government is merely harassing patients -- himself included -- who have a legitimate right to use the drug for managing pain due to multiple sclerosis, cancer and a host of other illnesses.



Washington voters approved the use of marijuana for certain medical conditions through a citizens initiative in 1998.
"Since they don't like medical marijuana, this is an attack on the people that support it," said Sarich, who insists he's no drug dealer. The nominal sums CannaCare collects go into supporting medical marijuana users, he said.

Only a few ounces of pot were found in the raid, and Sarich said the bulk of the seized crop was unrooted cuttings and starter plants. He also said the $1,020 drug agents seized in the raid was for his $1,103.56 Snohomish County PUD bill.

The raid's ultimate end remains unclear. Alloway said he referred the information to federal authorities because of the pot-growing operation's size.

Jeff Eig, spokesman for the Seattle division of the U.S. Drug Enforcement Administration, declined to comment.

Meanwhile, the Los Angeles Times reported on its Web site that the DEA said federal agents had raided 11 medical marijuana outlets in Los Angeles on Wednesday and seized several thousand pounds of marijuana, along with weapons and money.

Washington law allows possession of marijuana in doctor-approved cases but makes no provision for obtaining it, forcing patients who cannot grow enough to buy from others -- sometimes resorting to patronizing street-corner dealers.

Sarich, however, has flouted the statute by announcing that CannaCare will provide pot plants to patients. He and an associate, John Worthington, whose Renton home was also raided last week, said the police action was politically motivated retaliation.

Sarich also believes that because the state has no list of registered medical marijuana patients, CannaCare was targeted because it has contact information for more than 1,200 users.

That incursion into patient privacy worries advocates at the American Civil Liberties Union at least as much as the bust itself.

Alison Chin Holcomb, director of the Washington ACLU's Marijuana Education Project, said Sarich might have forced the government into it.

"He certainly wasn't afraid of getting the attention of law enforcement," she said. "He put himself out there on the radar."

Worthington recently sent documents alleging drug-enforcement excesses by Alloway to the state House and Senate judiciary and health care committees. He sent another letter to the State Patrol, accusing the detective of tampering with evidence.

"They went after me because I'm an activist, and I've been terrorized out of growing," said Worthington, whose home contained six marijuana plants, according to a Kitsap County Sheriff's Office document. "I can't have my kids frisked like they're criminals. That was disgusting. I'm not Al Capone -- I'm a dad."

Alloway, who works for the Bremerton Police Department, denied the allegations of wrongdoing on Wednesday.

P-I reporter Casey McNerthney can be reached at 206-448-8220 or caseymcnerthney@seattlepi.com.

Medical experts weigh in on Lyme disease





By Laura Kenyon

Amidst the start of an unprecedented investigation by Connecticut Attorney General Richard Blumenthal into Lyme disease treatment guidelines, victims of and experts on the disease are speaking out about its precarious place in the medical world.

In the second of two articles about Lyme disease, the Advertiser considers the varying opinions medical professionals hold regarding such guidelines, the existence of chronic Lyme disease, and long-term antibiotic treatment.
The previous article, published in last week’s issue, focused on local victims.

Freedom of Choice

According to the Centers for Disease Control, 1,810 cases of Lyme disease were reported in Connecticut in 2005, more than any other state besides Massachusetts, New Jersey, New York and Pennsylvania.

In October, the Infectious Diseases Society of America (IDSA) released an updated version of its 2000 Lyme treatment guidelines, which are often used by doctors and insurance companies to determine treatment.

Prompting national contention from many organizations, doctors and sufferers, the guidelines discourage the prolonged use of antibiotics to treat lingering symptoms, saying it “has not proven to be useful.”

They also conclude that there is no “convincing biologic evidence” for the existence of “chronic” or “post-Lyme syndrome.”

These particular findings prompted Mr. Blumenthal, he told the Advertiser, to worry that treatment choices and coverage for long-term Lyme sufferers would be determined by government officials or insurance companies rather than patients and their physicians.

In November, he filed a Civil Investigative Demand to look into possible anti-trust violations by the IDSA during the development of its new guidelines.

The Lyme Disease Association (LDA), a nonprofit organization “representing more Lyme disease patients than any organization in the United States,” quickly issued a press release applauding his move as “vitally necessary to protect the welfare of chronic Lyme patients nationwide.”

Clinical guidelines currently drive the standard of care, it said, and are sometimes used to deny treatment reimbursement. The IDSA guidelines list as “not recommended” “most of the conventional medical treatments prescribed by physicians as well as alternative treatments often chosen by patients for any Lyme manifestation.”

Dr. David Reed, New Canaan’s assistant director of health, does not believe IDSA had “ulterior motives” or “some sort of political agenda.” Calling the attorney general’s move “highly unusual,” he said it will have “repercussions.”

“These are nonprofit organizations. They don’t have, in my opinion, profit motives,” said Dr. Reed, who declined the opportunity to speak about chronic Lyme or long-term antibiotics.

First Selectman Judy Neville, who battled the disease for seven years in the 1990s, said treatment choices should be made only by patients and their doctors and Mr. Blumenthal is “doing what is necessary to protect Lyme patients.”

The Lyme Disease Association contends that the guidelines will negatively affect the number of treating physicians “since clinical discretion is not recommended by the guidelines” — a statement that Dr. Raymond Dattwyler, chief of Allergy, Immunology and Rheumatology at Westchester Medical Center and one of the authors of the IDSA guidelines, said is false.

“I think that one should really read the guidelines first before they should really make any judgments,” he told the Advertiser Friday. “They’re guidelines. They’re not cast in stone, and ultimately it states that that they allow individuals’ physicians to make their own judgments.”

Many Sides

Dr. Steven Phillips of Wilton, who served as president of the International Lyme and Associated Diseases Society (ILADS) from 2003-05, estimates that more than 25 percent of Lyme victims develop chronic symptoms and finds it “unsettling” the IDSA would exclude “a significant percentage of the Lyme disease population” in its findings.

“A great number of patients derive benefits from long-term antibiotics,” he told the Advertiser.

Chronic Lyme has been documented in thousands of medical journals, he said, but in composing its guidelines the IDSA referred to just 400 of more than 10,000 studies, many of which support the existence of chronic Lyme.

“If they’re going to pick a random sample,” he said, “it has to be random.”
They should have taken a “more even stance,” he added.

Dr. Dattwyler said between everyone who worked on the IDSA guidelines, “we probably read the overwhelming majority of stuff that’s ever been published on Lyme disease.”

The guidelines cited 405 papers. They were chosen, Dr. Dattwyler said, based on criteria including study design and the quality of the publishing journal. The group primarily choose articles in the “premier” journals, as rated by the National Library of Medicine, such as the New England Journal of Medicine, Nature and Annals of Internal Medicine.

“It’s really just a review of the literature published in respected medical journals,” he said, adding that there are “some really bizarre papers” out there.

“Most of us wrote a lot of these papers,” he said, citing one of his own published in the New England Journal of Medicine.

Both ILADS and IDSA offer guidelines for Lyme disease, and both differ in their findings.

While IDSA concludes that long-term antibiotic treatment “is not proven to be effective and may be dangerous,” and that there is no “convincing” evidence for the existence of “so-called ‘chronic’ Lyme disease,” ILADS believes antibiotic treatment should be “tailored to the individual” and cites chronic Lyme as “a growing epidemic.”

The 30-year-old daughter of New Canaan resident Judy Larson, who has battled Lyme since age 12 and was featured in last week’s Advertiser, initially improved while on intravenous antibiotics, but suffered “toxic” side effects — one forcing the removal of her gall bladder.

On the other side, New Canaan Director of Human Services Cheryl Jones was on intravenous antibiotics for four months in 2000 and oral antibiotics for more than a year, and said “for me, (they) were the only choice.”

Ms. Jones was initially diagnosed with Multiple Sclerosis in 1990 and believes the Lyme was overlooked during the next 10 years — not a rare story in either direction, according to Dr. Dattwyler.

Many people — “80 percent or more,” he said — are misdiagnosed with Lyme disease when they really have something else. That is why IDSA states that patients who believe they have “chronic” Lyme symptoms should ensure they do not in reality have another affliction, such as Multiple Sclerosis or cancer.

A year-long study at the Yale University Lyme Disease Clinic that studied 209 patients with a “presumptive diagnosis” (by their physicians, themselves or both) — published in the March 1, 1998, Annals of Internal Medicine and cited by Dr. Dattwyler — found that only 21 percent met the criteria for active Lyme disease, 19 percent were previously but no longer infected, and 60 percent had no evidence of current or previous infection.

A study published in the June 24, 2003, issue of Neurology, cited by Dr. Phillips, found that patients given 28 days of antibiotic treatment (ceftriaxone) showed improvement in “disabling fatigue.” The study also found adverse side effects and little or no improvement in cognitive or persistent function, however, and concluded that it “does not support the use of additional antibiotic therapy with parental ceftriaxone in post-treatment.”

The study was penned by Stony Brook University Medical Center doctors, including Dr. Dattwyler.

Authors of an April 15, 2004, Journal of Clinical Investigation article explored both sides, stating that a small percentage of patients with “well-documented Lyme disease” may develop post-Lyme disease syndrome symptoms (including musculoskeletal pain and fatigue) for months or years after antibiotic treatment, but that prolonged antibiotic therapy “may be harmful.” When treating those with chronic Lyme, they advocated following the guidelines for chronic fatigue syndrome or fibromyalgia, a “similar” affliction.

The Future

“The biggest problem,” Ms. Larson said, “is nobody really knows what the answer is and it’s a very elusive thing that can take many forms. There needs to be a lot more research on it. I think it’s an epidemic that people haven’t really recognized in the medical community.”

Many diseases, “not only tick-borne infectious diseases,” are in need of further study, Dr. Dattwyler said, but organizations such as the National Institutes of Health and the Center for Infectious Disease need more funding in order to do so.

While its existence may be controversial, he said that the pain felt by those diagnosed with chronic Lyme disease is real and modern medicine does not always provide them with the answers they are seeking.

The bottom line on both sides, Dr. Phillips said, is that patients must become educated about Lyme and other diseases, and become “their own advocates.”

© Copyright 2006 by Hersam Acorn newspapers

Tuesday, January 16, 2007

Pragmatic approach to MS





The Dominion Post | Tuesday, 16 January 2007

Some multiple sclerosis sufferers will only ever experience mild symptoms over their lifetime while others experience slowly worsening disability over many months or years. Kelly Andrew talks to Helen Roddick, who has been living with the disorder for 14 years.

Helen Roddick's father, a GP, wept in the neurology ward at Christchurch Hospital when he found out she had multiple sclerosis. Helen, then aged 24 and in her final year of nursing training, took a more pragmatic approach to her diagnosis. She hauled out her textbooks to look up the disease and find out exactly what she was dealing with. The symptoms listed - including visual and sensory disturbances - mirrored what she experienced in her first attack.

"I started feeling dizzy at work and then I vomited continuously. I went to bed and my vision went double so I went to emergency at the hospital."

Helen was referred to a neurologist by her GP after she left hospital. Tests, including a lumbar puncture and blood tests, confirmed the MS diagnosis within a week. Helen's father recognised the symptoms and had already quietly suspected that she had the neurological disease.

She is one of up to 4000 New Zealanders with MS - the exact number is unknown till a new nationwide study of its prevalency is completed later this year. The disease attacks the central nervous system, damaging the protective sheath that covers nerves and disrupting signals from the brain. The name refers to multiple areas of scarring (sclerosis) in the brain and spinal cord. At present there is no cure but drugs such as glatiramer and beta interferon can slow its progression and muscle relaxants can help control some of the symptoms.

The course of MS varies widely from person to person - some people will only ever experience mild symptoms over their lifetime while others experience slowly worsening disability over many months or years.
Now 38, Helen has been living with the disorder for 14 years. It has gradually worsened, but she says she is used to living with a disease she describes as "strange".

The symptoms strike suddenly and then ebb away only to return without warning at a later date. The effects are variable depending on the which part of the brain and spinal chord is struck by inflammation and the resulting sclerosis.
In July, Helen lost vision in her right eye because of inflammation of the optic nerve caused by MS. For the past six years she has had to use a walking stick, and more recently a walking frame, to get around. With her limited eyesight she is very unsteady on her feet at night.

"I walk very slowly and I don't pick up my feet as fluidly. Unless I'm concentrating I'll trip myself up."

She has had MRI scans of her brain that show numerous plaques, or lesions, but says this does not necessarily reflect the severity of her condition. "That's the funny thing. I'm still mobile and active. It's a strange disease. But I'm definitely slower, like when I'm getting off the bus I always have to apologise to the drivers.

"My big problem is muscle fatigue in my thighs and arms. It's a funny thing and hard to describe. I know some MS people fall asleep at the drop of a hat."

Every second day a Nurse Maude helper gives Helen an injection of the government-funded drug beta interferon.
There are many theories on possible treatments for MS, some sufferers turn to oxygen therapy using hyperbaric chambers more commonly used in diving medicine, B12 injections, and special diets. Helen does not subscribe to these herself, but says if they work for others then they should stick with them.

Though many people see MS as an older person's disease, symptoms usually appear between the ages of 20 and 50 with a peak in the early 30s. Women, people with European ancestry, and those who live in cooler climates are more at risk and generally it becomes more common the further one moves away from the equator. The prevalence of MS is much higher in regions such as New Zealand's South Island, Scotland and Canada than it is in tropical and sub- tropical areas.

For this reason, MS is relatively common in Christchurch and in Helen's experience everyone knows somebody who has it.
"Most people understand a bit about it and they're willing to help you. It's only isolated cases where people are stupid. Once someone said to me that I was very intelligent for someone with MS."

There have been other occasions where people have assumed she is drunk or on drugs because she looks wobbly on her legs. "There was a young bloke, about 16, on Colombo St who said to me, "What drug can I take to be as wasted as you?" I burst out laughing."

The cause of MS is still not known but both genetic and environmental factors are important. Near relatives of those with MS have an increased risk. Exposure early in life to a viral infection that has a long-term effect on immunity is also believed to be likely.

Helen had bacterial meningitis as a child and she speculates this could be one of the factors that made her vulnerable to MS as an adult. Like many other MS patients she is taking part in a Christchurch School of Medicine study led by neurologist Bruce Taylor investigating a possible link between low sun exposure over the course of a lifetime and MS.

Multiple Sclerosis Society national director Nola Rawson says the results of the study, expected in July or August, are eagerly awaited internationally because of hopes they will shed some light on the causes of the disease and explain its geographic pattern.

She is concerned about the lack of respite care available to people who are severely affected by MS. There have been cases of young people being put into resthome care, which Ms Rawson says is unacceptable.

Despite the difficulties she has faced, Helen is philosophical about her experience of MS and grateful that she is still able to lead a reasonably independent life.

"It pisses me off that it's happening to me. But I've had it for such a long time that I'm used to it. I've seen people who are very bad with it and I feel sad for them, some of them are younger than me. Some people have a negative view of MS, they think they'll end up in a wheelchair within six months but I understand it's a long-term thing."

Common symptoms of MS include:

Weakness or poor coordination of the limbs
Impaired balance or instability walking
Sensory disturbances
Blurred or double vision
Impaired urinary or sexual function
Cognitive dysfunction such as impaired memory or concentration
General fatigue

Parasitic Infection Is Found To Benefit MS Patients in Study





Patients with multiple sclerosis who also happen to have an intestinal parasite appear to have significantly fewer relapses and better outcomes than other MS patients, a new study found.

The finding suggests that when the body's immune system is occupied with an external threat, it may be less likely to misfire, which happens in conditions known as autoimmune disorders. Multiple sclerosis is an autoimmune disorder that attacks the myelin sheath that protects nerve fibers.

The study tracked 12 multiple sclerosis patients who were found to have an intestinal parasite and compared them with 12 other patients. Over four years, there were stark differences. There were three relapses among the patients who had the intestinal infection and 56 relapses in the other group.

Patients with the parasitic infection also had minimal changes in disability scores compared with the other group, according to a study in this month's Annals of Neurology by Jorge Correale and Mauricio Farez of the Ra?l Carrea Institute for Neurological Research in Buenos Aires.

The study suggests that one reason for the apparent increase in autoimmune disorders in recent years could be the decline of infectious diseases in certain countries. Because parasites often cause long-lasting infections, the researchers hypothesized that such infections could make persistent demands on the body and thereby reduce the likelihood that the immune system will attack healthy tissue.

-- Shankar Vedantam

Doctors knew I had MS for 11 years before they told me





By ISLA WHITCROFT

A father's 11-year nightmare struggle to be diagnosed with MS has exposed the scandal of how consultants withhold bad news:

On a cold December night, PC Gary Dimmock finished his shift and drove to Beachy Head. He had often spent time talking people out of jumping from the notorious suicide spot, but this time he wasn't there to save anyone - he was thinking of taking his own life.

'It would have been the end to all my problems,' says Gary, 42. For ten years, he had suffered from a range of debilitating symptoms that left him barely able to function.

Despite this, his GP and a number of specialists refused to acknowledge there was anything seriously wrong with him - one even accused him of making it all up.

'In the early stages, it had been easy to dismiss each symptom as bad luck, but by that night in 2002, I was in a terrible state,' says Gary.

'I was dropping things and dragging my feet. I suffered from dizziness and double Ovision, as well as agonising pins and needles in my legs. Sometimes they went numb and occasionally when I got out of bed I would collapse in a heap.'

He'd also suffered chronic urinary infections and was losing weight rapidly - in one month alone, he lost two stone, despite eating up to 5,000 calories a day. 'I was so tired I could easily have slept for 24 hours at a time,' he recalls.

'I was too exhausted to give my best at work - and once or twice even fell asleep when parked in a police car. My colleagues commented on how gaunt and ill I looked. I was starting to take time offsick and though my bosses were supportive, I felt guilty.'

Gary was often too unwell to play with his toddler son, Kian, while his tiredness, irritability and worry about his health was putting a strain on his marriage to Lisa, now 41.

In an increasingly desperate search for a diagnosis, Gary consulted his GP, a consultant neurologist and three consultant ophthalmologists. All insisted his symptoms weren't linked and there was nothing seriously wrong with him. Gary and Lisa, a former WPC, then turned to the internet, where they dis-covered he had the classic symptoms of multiple sclerosis.

'But when I raised the issue of MS with a GP locum in early December 2002, he called me a cyberchondriac - someone who uses the internet to misdiagnose themselves. I left feeling as if I had a psychological problem,' says Gary.

'By the time I drove to Beachy Head, I was worn down. No one seemed to believe me and I even began to wonder if I was subconsciously malingering or going mad. But as I sat in my car, I saw sense. I thought of my children: Sophie, then 12, and Kian. They needed their dad - whatever physical state he was in.

'I know from my job how much collateral damage suicide can inflict - I simply wasn't prepared to do that to my family. So I turned the car around and went home, determined to get to the bottom of what was wrong with me.'

As Gary and Lisa had suspected, he was suffering from the neurological disease MS, which affects around 85,000 people in Britain. It is caused by damage to myelin, the protective sheath that surrounds the nerves which make up the central nervous system. Messages between the brain and the body become scrambled, resulting in a variety of physiological symptoms.

For the 11 years from 1992 to 2003 that Gary went undiagnosed, it is clear from his medical notes that the doctors who investigated his recurring symptoms had strong suspicions he had MS, but decided not to tell him. Nor did any of them recommend he had the final tests - an MRI scan and lumbar puncture - which would confirm the diagnosis.

This delay not only caused him great mental distress, it meant he was unable to take medication which could have alleviated or slowed down his symptoms. It's not only a story of personal anguish, but one which highlights an extraordinary anomaly - that at a time when we talk of patients' rights and openness, doctors are still able to withhold vital information.

As far back as 1992, Gary's GP had written 'impression MS?' on his notes. Three years later, in a letter to the GP, a neurologist suggested Gary could be in the early stages of demylenation - this refers to the destruction of the myelin sheath around the nerves, indicative of MS. In the same letter, the neurologist says that if more symptoms occurred, then Gary should be investigated more fully for MS - something that didn't happen until 2003.

In 1997, an ophthalmic surgeon, who had seen Gary after yet another episode of double vision, wrote to the GP saying the most likely underlying diagnosis was 'disseminated sclerosis'. From 1992 until Gary's diagnosis in 2003, the correspondence between various doctors is littered with similar references to the first stages of MS.

In some letters, some of the specialists express a reluctance to carry out an MRI scan because they would then, as one wrote, be 'duty bound to confess the diagnosis'.

By 2003, yet another ophthalmic surgeon wrote to the neurologist high-lighting his suspicion that Gary had MS.

The specialist wrote back saying he considered it very likely that Gary was suffering from the condition, but because no conversation about the subject had taken place between him and the patient, he had 'left it unsaid'.

Gary saw three types of specialists, some up to ten times, but all seemed oblivious to the suffering their silence was causing him.

And as well as keeping him in the dark about his probable diagnosis, they continued to treat each symptom individually.

Gary had to undergo a series of unnecessary and often unpleasant tests, including rectal examinations for prostate cancer and barium meal X-rays for irritable bowel syndrome. The tests came back negative.

By June 2003, Gary's symptoms had worsened: he was exhausted, tormented by pins and needles and worried whether he was going to wake up in the morning with double vision, a dragging foot or both. His GP made yet another appointment with a neurologist, who finally referred Gary for an MRI scan.

'The neurologist said he thought it was about time we found out what was going on and I just accepted this because I had been told so many times there was nothing wrong,' says Gary.

After a lumbar puncture, Gary and Lisa were finally told that he did, indeed, have MS. 'Though it was obviously devastating and frightening, it was also a relief,' says Gary.

'It meant I wasn't going mad and that at last I knew what I was dealing with and could start to help myself.

'For the first time in years, I felt in control of my body and health. It meant that Lisa and I could start to plan our future together as a family dealing with a problem.

'She has said that from that day on, my personality changed and I became happier - more like the old Gary I was before I became ill.'

When, a few weeks later, Gary confronted his neurologist with the fact the specialist had known all along that about the illness, the response was unequivocal: 'I didn't lie to you. I just didn't tell you the truth.'

Gary and his wife were stunned. 'Lisa asked him to repeat what he had said,' he says.

'I felt like punching him - and I am not a man who agrees with violence. There was a long silence and then, hand in hand, Lisa and I walked out of the room and out of the hospital.'

The consultants' actions may seem extraordinary, but they can be explained by the little-known Therapeutic Privilege. This is a legal phrase used to describe the action of withholding medical information from a patient.

'Until recently, it was relatively common for doctors to withhold vital information from patients,' says Dr Daniel Sokol, a medical ethicist at Keele University.

'It was partly a cultural issue - the notion of paternal benevolence was rife among many doctors and patients - but it also had a practical basis.

'In the past, cancer, for example, was pretty much a death sentence, so doctors often worked hard to keep the news from their patients for as long as possible.

'But over the past 40 years, as survival rates from cancer increased and treatments became available, oncologists began to follow a policy of openness.

'Though they will be careful about how and when they disclose information, they pretty much tell you the truth as they go along.

'Now "non-disclosure" is more of an issue with neurological disorders such as MS because these are the diseases which are hardest to diagnose and carry devastating long-term consequences.'

It is true MS can be difficult to identify because it has symptoms in common with other conditions, and there is no single test that gives a cast-iron diagnosis.

'The official advice is that someone should be told as soon as a diagnosis of MS is considered reasonably likely - unless there are overwhelming patient-centred reasons for not doing so,' says Dr Lee Dunster, head of research at the MS Society.

'While there are patients who say they are grateful they weren't told immediately, the majority seem to favour being told as early as possible, so they can take decisions about lifestyle changes and therapies they might try.'

The British Medical Association advises its members not to with-hold information from patients.

'We encourage them to be active partners in decision making. If patients are not given sufficient and relevant information about their condition, the validity of their consent to any treatment is questionable,' says a spokesman.

According to Sharon Burton, senior policy adviser on ethics for the General Medical Council, there are only rare occasions when it would be appropriate to withhold vital information from a patient.

'This would be when the patient was clearly not in a fit emotional or mental state to be able to assimilate and deal with the information,' she says.

'In this case, the doctor should work with the carer or relative to find the best time to break the news to the patient.'

Crucially, Sharon points out that this situation should not be considered a long-term measure.

'Withholding information for the right reasons has a legal and ethical basis in very exceptional circumstances and not over one, two or more years.'

Last week, Gary Dimmock won a £10,000 out-of-court settlement against the East Sussex Hospital Trust. It has apologised for 'not sharing with him at an earlier stage that his symptoms may be attributable to multiple sclerosis'.

As part of the preparation for the legal case, Gary was given his medical notes.

'By the time I finished reading them, tears were running down my cheeks. There in front of me was 11 years of suffering, all the needless and unpleasant investigations I went through and the anxiety and worry I and my family suffered. I was sad and also very angry.

'If I had known about the MS earlier, then I would have done things very differently. Before 2000, we only had a daughter. Though I love my son to death and would never be without him, if I had known I had such a serious, life-changing ill-ness, we might have chosen not to have another child.

'My illness has moved on from the relapse/ remittance stage to the progressive stage. Though I am relatively well now, things could change tomorrow. So who knows what kind of father I will be in the next few years?

'In addition, we moved house and took on a much bigger mortgage. As the breadwinner of the family, I have no idea how much longer I will be able to pay it, so that is another worry.

'Perhaps most importantly, I would have approached my health differently. I would have started a regime of treatment which might have alleviated my symptoms.

'The first thing I did when I heard I had MS was to tell my boss, who was brilliant. He took me straight offshift work, which has greatly reduced my fatigue levels.

'This meant I was able to start a regime of gentle exercise, which is an important part of my treatment. Now I know what I am dealing with, I am far more positive and less irritable, which in turn means a happier home life.'

Gary is under the care of a new consultant who is very open - but he still finds it hard to trust him.

'Those doctors made a decision to deceive me and their decision put me and my family through hell,' he says. 'They didn't trust me to deal with my own health properly. It will take me a long time before I can trust doctors.'

Since the news of his settlement, Gary's solicitor, Gillian Solly, of Russell Jones & Walker, has received numerous calls from MS sufferers around the country who have struggled to get a diagnosis.

'I am not able to say that the practice of withholding medical information is commonplace, but there is certainly a need to get a debate going around the issue,' says Gillian.

'I don't believe that guidelines are the answer. Doctors should admit it goes on and start to talk openly about it so that everyone - including the patient - knows where they stand.'

As Gary puts it: 'In this day and age of medical awareness and diagnostic medicine, there is no reason why people shouldn't be told the truth as soon as possible.

'No one has the right to deceive you, especially about something as important as your health.'

Gary Dimmock is raising funds to pay for a mini-bus for the Eastbourne MS Society. To make a donation, call Freephone 0800 100 133. For more information about multiple sclerosis, contact www.mssociety.org.u

Results of Sativex® Phase III Neuropathic Pain Trials Demonstrate Benefits for High Need Treatment-Resistant Patients





15/01/2007

15 January 2007: GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain. These studies are part of a programme to generate data for the future expansion of the use of Sativex in Europe beyond Multiple Sclerosis (MS) into other pain conditions.
The results of the study in patients with neuropathic pain characterised by allodynia show that patients taking Sativex obtain clinically important improvements in their management of pain and quality of sleep. In comparison with placebo, statistically significant improvements were seen for key outcome measures, including a positive result in the primary analysis of patient response, the outcome measure recommended by regulatory authorities.

The results of the study in patients with painful diabetic neuropathy show that patients taking Sativex obtained substantial improvements in their pain, indeed among the highest level of response seen in the published literature. There was an abnormally large placebo response in this study, which means that the data are more difficult to interpret categorically.

Dr Stephen Wright, GW’s R&D Director, said, “Neuropathic pain is one of the most difficult types of chronic pain to treat. These studies focused on particularly high need patients, who were already taking the best available pain treatments, and yet still suffered severe pain. Even in this most difficult to treat population, Sativex has produced improvements over and above current treatments that are highly meaningful to the everyday lives of patients.”

These two studies form part of a programme of neuropathic pain trials conducted to date by GW and reinforce the large body of positive data already generated. These data contribute significantly to a future regulatory filing in the use of Sativex as a treatment for neuropathic pain. GW intends to continue to add to this evidence base.

Allodynia Study

This multi-centre double-blind, randomised, placebo-controlled parallel group study in 246 patients examined the effect of Sativex in patients with neuropathic pain characterised by allodynia. Allodynia is the occurrence of pain in response to a normally non-painful stimulus (e.g. clothes touching against the skin). It is often intense and can occur in patients suffering from a range of conditions that damage the peripheral nerves (e.g. nerve lesions, post-herpetic neuralgia). Patients in this study were being treated with a range of currently available analgesics, which were maintained during the course of the study.

The results of this study confirm the efficacy of Sativex. The responder analysis of the primary endpoint (the proportion of patients obtaining a clinically meaningful improvement in pain relief), was statistically significantly in favour of Sativex (p=0.03) for the full Intention to Treat (ITT) population. In addition, two of the key pain-related secondary efficacy endpoints, the Patient’s Global Impression of Change (p<0.03) and the assessment of sleep quality (p<0.01), were also statistically significantly in favour of Sativex. All the other secondary efficacy endpoints were in favour of Sativex.

European and US regulators recommend a responder analysis of the primary endpoint in pain studies as the key assessment of outcome. This analysis was positive and confirms that Sativex produces a clinically important benefit over and above currently available treatments in a meaningful proportion of otherwise treatment-resistant patients. An additional analysis of the mean endpoint data was strongly in favour of Sativex and approached statistical significance.

Diabetic Neuropathy Study

This multi-centre double-blind, randomised, placebo-controlled parallel group study in 297 patients examined the effect of Sativex in patients with painful diabetic neuropathy. Patients in this study were being treated with a range of currently available analgesics, which were maintained during the course of the study.

In this study, patients taking Sativex showed a 30% mean improvement in pain scores, among the highest level of response seen in the published literature. One third of Sativex patients achieved over a 50% improvement in pain. However, the study results are difficult to interpret due to an abnormally large response in the placebo group. As such, although all outcome measures compared to placebo are in favour of Sativex, they do not reach statistical significance.

With regard to safety, the pattern of adverse events in both studies was similar to that seen in other Sativex studies.

Peripheral neuropathic pain forms part of a regulatory strategy to obtain approvals for Sativex across major markets in a range of indications, including MS symptoms, central neuropathic pain and cancer pain. Sativex is the subject of an ongoing regulatory application in four selected European countries for the symptomatic relief of spasticity in MS. Upon initial approval, it is intended to extend the MS spasticity indication into other European countries through the mutual recognition procedure. Since the rules do not permit a parallel regulatory application in neuropathic pain, GW’s regulatory strategy for this indication is to continue to build the clinical evidence base whilst the MS spasticity regulatory process is ongoing. Hence, additional confirmatory trials have been under preparation for some months and ethics committee approvals obtained. With the benefit of today’s results, the designs of the additional studies can be finalised prior to their commencement. These studies will further contribute to a future regulatory submission in neuropathic pain.

Sativex is approved and marketed in Canada for the symptomatic relief of central neuropathic pain in MS, and is the subject of an ongoing regulatory submission in Canada for the relief of cancer pain.

Enquiries:
GW Pharmaceuticals plc Today: +44 (0)20 7831 3113
Dr Geoffrey Guy, Chairman
Justin Gover, Managing Director
Dr Stephen Wright, R&D Director

Financial Dynamics Tel: +44 (0)20 7831 3113
David Yates / Ben Atwell

About GW Pharmaceuticals plc
GW was founded in 1998 and listed on the AiM, a market of the London Stock Exchange, in June 2001. Operating under licence from the UK Home Office, the Company is developing cannabis-derived pharmaceutical products for patients with multiple sclerosis, neuropathic pain, cancer pain, spinal cord injury, rheumatoid arthritis, and other severe medical conditions.

GW has assembled a team of over 100 scientists with extensive experience in developing both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW is dedicated to developing treatment options that alleviate pain and other neurological symptoms in patients who suffer from serious ailments.

For further information, please visit the Company’s website: www.gwpharm.com

About Neuropathic Pain
Neuropathic pain is caused by damage to or dysfunction of the nervous system. It is usually chronic and accompanied by unpleasant burning or shooting sensations, or extreme sensitivity to touch.

It is estimated that at least 1 per cent. of the world’s population suffers from neuropathic pain, including over 600,000 patients in UK.

Neuropathic pain can be difficult to diagnose and may be confused with nociceptive pain (caused by bodily injury - ‘visceral’ or ‘somatic’). The presence of allodynia can confirm that the pain experienced by the patient is truly neuropathic.

Neuropathic pain can be associated with many conditions including multiple sclerosis, stroke, cancer, spinal cord injury, physical trauma and peripheral neuropathy resulting from diabetes. It can also occur in patients who have previously suffered from shingles, a condition known as post-herpetic neuralgia.

Neuropathic pain is one of the most difficult types of chronic pain to treat. Since treatment options are limited, doctors often prescribe a combination of therapies in an attempt to relieve symptoms.

Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine





Oral Cladribine on Track to Become First Oral Disease Modifying Treatment for Multiple Sclerosis

GENEVA, Switzerland, January 16, 2007 /PRNewswire-FirstCall/ -- Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety of Merck Serono's proprietary oral formulation of cladribine for the treatment of relapsing forms of multiple sclerosis (MS).


"The completion of patient enrollment into the CLARITY pivotal trial is a major milestone in the development program of oral cladribine," said Franck Latrille, Merck Serono's Head of Product Development. "It brings us one step closer to our objective of offering patients the first oral therapy for first line treatment of multiple sclerosis, with the convenience of short courses of therapy given intermittently."

The CLARITY study is a two-year (96 weeks), randomized, double-blind, placebo-controlled, international trial. It enrolled more than 1,300 patients and will provide data on key endpoints including clinical relapses, disability progression and magnetic resonance imaging (MRI). Study participants have been enrolled in one of the three arms of the study to receive one of two different dose regimens of oral cladribine or matching placebo tablets. In the study, oral cladribine is given in two or four treatment cycles in the first year, with each cycle consisting of daily administration for five consecutive days, which means study patients take oral cladribine therapy for only 10 or 20 days during the year. In the second year, two treatment cycles are administered.

The increased convenience resulting from the oral intermittent administration of oral cladribine has the potential to address an important unmet medical need in patients with MS.

Oral cladribine was designated a Fast Track product by the US Food and Drug Administration (FDA) in September 2006. Under Fast Track designation, oral cladribine is eligible for Priority Review and the FDA may consider portions of the marketing application for review before the New Drug Application (NDA) is completed.

About oral cladribine

Merck Serono's proprietary oral formulation of cladribine is currently being evaluated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that interferes with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are involved in the pathological process of MS. Through its differentiated mechanism of action, oral cladribine may offer a safe and effective new option to patients with MS.

About Merck Serono and multiple sclerosis

Merck Serono is a leader in multiple sclerosis (MS) with Rebif(R) (interferon beta-1a), a disease-modifying drug used to treat relapsing forms of MS, which is registered in more than 80 countries worldwide. In addition to Rebif(R), the Company also offers a second therapy within its US portfolio of MS therapies: Novantrone(R) (mitoxantrone for injection concentrate) for worsening forms of MS. Full prescribing information for these products can be obtained by contacting the Company or visiting its website. Additional therapeutic options are currently under development at Merck Serono, including oral cladribine, currently in Phase III and potentially the first oral therapy for MS, as well as several products in early stage development including: osteopontin, an MMP-12 inhibitor, a JNK inhibitor and interferon beta:Fc. Merck Serono also is taking a leading role in developing an understanding of the role of genetics in MS, with a whole genome scan currently underway.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the nervous system and is the most common, non-traumatic, neurological disease in young adults. The World Health Organization estimates that up to 2.5 million people suffer from MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Forward-looking statements

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Merck Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Merck Serono's current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Merck Serono's ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of any government investigations and litigation. Merck Serono is providing this information as of the date of this press release, and has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

About Merck Serono

Merck Serono is a global biotechnology leader, with sales in over 90 countries. The Company is the world leader in reproductive health, with Gonal-f(R), Luveris(R) and Ovidrel(R)/Ovitrelle(R). It has strong market positions in neurology, with Rebif(R), as well as in metabolism and growth, with Saizen(R), Serostim(R) and Zorbtive(TM). The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on establishing new therapeutic areas, including oncology and autoimmune diseases.

Bearer shares of Merck Serono S.A., the holding company, are traded on the virt-x (SEO) and its American Depositary Shares are traded on the New York Stock Exchange (SRA).

About Merck

Merck is a global pharmaceutical and chemical company with sales of EUR 5.9 billion in 2005, a history that began in 1668, and a future shaped by about 35,000 employees (including Merck Serono) in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 73% interest and free shareholders own the remaining 27%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

CONTACT: Merck Serono, 9 Chemin des Mines, 1211 Geneva 20, Switzerland.Corporate Media Relations, Tel:+41-22-414-36-00, Media Relations, USA.Corporate Investor Relations, Tel:+41-22-414-36-01, Investor Relations,USA, 9 Chemin des Mines Corporate Media Relations Corporate InvestorRelations, 1211 Geneva 20 Tel:+41-22-414-36-00 Tel:+41-22-414-36-01,Switzerland Media Relations, USA Investor Relations, USA.www.merckserono.ch Tel :+1-781-681-23-40 Tel:+1-781-681-25-52

Ticker Symbol: (NYSE:SRA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Oxford BioMedica Announces Publication of Avian Trangenic Results in Leading U.S. Scientific Journal





OXFORD, England - Jan. 16, 2007-Oxford BioMedica (LSE: OXB), a leading gene therapy company, and its collaborative partners in the field of avian transgenics, Viragen, Inc. (AMEX: VRA) and Roslin Institute, today announced that the Proceedings of the National Academy of Sciences of the United States of America (PNAS), a leading scientific journal, has published an article profiling the avian transgenic (OVA(tm)) system's ability to express two therapeutic proteins in the whites of eggs of transgenic hens. The OVA(tm) System is being developed as a novel, large-scale biomanufacturing alternative, capable of cost-effectively expressing many types of therapeutic proteins.

The article, entitled, "Oviduct-specific expression of two therapeutic proteins in transgenic hens", reports on the production of two protein drug candidates: a humanized monoclonal antibody being developed by Viragen for advanced malignant melanoma and interferon beta-1a, which is currently marketed under two competing brand names for the treatment of Multiple Sclerosis (MS), as Avonex(r) (Biogen Idec) and Rebif(r) (Serono).

Article Summary:

Recent advances in avian transgenesis have led to the possibility of utilizing the laying hen as a production platform for the large-scale synthesis of pharmaceutical proteins. Ovalbumin constitutes more than half of the protein in the white of a laid egg, and expression of the ovalbumin gene is restricted to the tubular gland cells of the oviduct. Here we describe the use of lentiviral vectors to deliver transgene constructs comprising regulatory sequences from the ovalbumin gene designed to direct synthesis of associated therapeutic proteins to the oviduct. We report the generation of transgenic hens that synthesize functional recombinant pharmaceutical protein in a tightly regulated tissue-specific manner, without any evidence of transgene silencing after germ-line transmission.

According to Viragen Vice President, Dr. Karen Jervis, who is Managing Director of Viragen's Scotland operations, additional avian transgenic milestones are expected shortly: "We are very pleased that the PNAS article chronicles our 'proof-of-principle' studies resulting in successful germline transmission of two therapeutic proteins, and we expect to report excellent new results with a third protein-drug candidate by the end of this month, assuming positive confirmations," stated Dr. Jervis.

Professor Alan Kingsman, Oxford BioMedica's Chief Executive Officer commented: "We are delighted by the progress of our collaborative partners towards the commercialisation of the OVA(tm) System. This technology could address a substantial need in the biopharmaceutical industry for efficient, high-volume production of biological products."


For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive
Tel: +44 (0)1865 783 000

Viragen, Inc:
Director of Communications, Doug Calder
Tel: (954) 233 8746

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications
Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:

Tony Stephenson/ Holly Griffiths
Northbank Communications
Tel: +44 (0)20 3008 7550


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes two clinical candidates and a preclinical targeted antibody therapy, which is being developed in collaboration with Wyeth. The Company has started Phase III development of its lead cancer immunotherapy product, TroVax, in renal cancer and multiple Phase II trials in various cancer settings are ongoing or planned. In neurotherapy, the Company's lead product, ProSavin, is expected to enter clinical trials in Parkinson's disease in 2007. The preclinical pipeline includes gene-based products for vision loss, motor neuron disease and nerve repair.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 70 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed, Virxsys and Kiadis; and has licensed technology to a number of companies including Merck & Co, Biogen Idec, GSK and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk


2. The OVA(tm) System

Viragen holds the worldwide exclusive license to commercialize the OVA(tm) System (Avian Transgenic Biomanufacturing) as granted by the Roslin Institute (Scotland). The project is designed to develop the chicken into a pharmaceutical bioreactor, one that can meet the growing need for protein-based human therapeutics. Based on the creation of lines of transgenic hens which have been engineered to produce a target protein in their eggs using the LentiVector(r) gene delivery system licensed from Oxford BioMedica plc, this technology is being developed as an efficient and economical alternative to standard bio-manufacturing techniques, having many apparent advantages in ease of scale-up, lower costs of production and quality of product produced.

This project has been funded in part from a grant awarded by the Scottish Executive's "SPUR Plus Program", designed to support significant technological advances being made in Scotland.

3. Proceedings of the National Academy of Sciences (PNAS)

PNAS is one of the world's most-cited multidisciplinary scientific serials. Since its establishment in 1914, it continues to publish cutting-edge research reports, commentaries, reviews, perspectives, colloquium papers, and actions of the Academy. Coverage in PNAS spans the biological, physical, and social sciences. PNAS is published weekly in print, and daily online in PNAS Early Edition. For more information, please visit: http://www.PNAS.org


4. Viragen, Inc.

With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product and product candidate portfolio includes: Multiferon(r) (multi-subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, other niche cancer indications and selected infectious diseases; VG101, a humanized monoclonal antibody that binds selectively to an antigen over-expressed on Stage IV malignant melanoma tumors; and VG102, a highly novel humanized monoclonal antibody that binds selectively to an antigen that is over-expressed on nearly all solid tumors. We are also pioneering the development of the OVA(tm) System (Avian Transgenics), with the renowned Roslin Institute, the creators of "Dolly the Sheep", as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens.


For more information, please visit: http://www.viragen.com

Monday, January 15, 2007

With drug prices, look before leaping





By Boston Herald editorial staff
Sunday, January 14, 2007

The House on Friday passed a bill requiring the government to negotiate drug prices for Medicare without really thinking through the issues. If the Senate doesn’t stop this runaway legislative freight train, surely the president will.

Backers claim there’s no reason for Medicare not to adopt the strategy of the Veterans Administration, which does negotiate prices downward from the 24 percent discount off the wholesale price (about as real as an automobile sticker price) the government requires for sales to the VA. But the law establishing a new Medicare drug benefit explicitly forbids the government to negotiate with drug suppliers.

The VA has a bargaining chip the House leaders forbade in drawing up their bill: a “formulary,” a list of approved drugs for its patients. If a drug company doesn’t negotiate what VA considers satisfactory additional discounts, its drugs don’t make the list. (Patients can appeal for an unapproved drug, but that means taking on the VA bureaucracy.)

Without a Medicare-wide formulary (the subsidized Part D plans have their own formularies and do their own negotiating), it’s hard to see how the government can do better than private Medicare drug plans are doing now - indeed, the Congressional Budget Office and Medicare say it can’t.

The VA model is a poor one. Only 19 percent of new drugs approved since 2000 have made it onto the VA formulary. Tysabri for multiple sclerosis is on every Part D formulary, but not the VA’s. Not one of the drugs approved by the Food and Drug Administration as a priority since 2000 is on the list. Frank Lichtenberg, an economist at the Columbia University Graduate School of Business, has estimated that “the use of older drugs in the VA system may have reduced life expectancy by 2.04 months” per person.

Medicare’s Part D plans are doing better than expected, covering more than 90 percent of the eligible. The costs ($30 billion last year, $26 billion below initial estimates) are coming in below initial estimates. And 2 million VA patients are so unhappy with the VA formulary that they are using Part D.

Medicare’s Part D arrangements surely can be improved, but this half-step toward outright price controls is not the way to go.

Drug hope in GM hens' eggs





The West Australian - Jan. 15, 2007

Scottish scientists have bred a flock of genetically modified chickens which they hope will lay eggs that can be used to produce cheap drugs to fight life-threatening diseases.

Researchers at the Roslin Institute have reportedly created chickens which produced complex human proteins in their eggs that could be extracted and developed into drugs to fight diseases including cancer and multiple sclerosis.

Researchers injected human genes into the hens' DNA to make the birds secrete human proteins in the whites of their eggs - chickens have previously been produced with altered DNA but their ability to make the important proteins usually disappeared within a generation or two.

The Roslin team reportedly bred five generations of chickens and all produced high concentrations of the pharmaceuticals.

WA Institute for Medical Research Professor David Ravine said the process could have huge economic potential for reducing the costs of creating pharmaceuticals. "While there appears to be no real benefits for scientists to use this process for research purposes, local biotechnology companies may well be interested in the development for the creation of drugs in a more cost-efficient manner," Professor Ravine said.

American biotechnology company Viragen collaborated with the institute on the project, which was designed to substitute chicken eggs for the expensive bioreactor vessels used to make protein-based drugs.

Australian Medical Association WA vice-president Richard Choong said it was not controversial to create drugs for humans using proteins from genetically modified chickens.

"Humans had been using animals as a source of medicine for years, so this should not raise ethical concerns," Dr Choong said. "Often there's an emotion attached to using a human gene but a human gene is like any other gene, it's a quoted sequence in the DNA strand used for certain proteins. If they can ensure the purity of the protein, I think it is fine." Dr Choong did not think the chickens would be changed significantly because researchers wanted to create only one protein at a time.

The Scottish scientists also created Dolly the cloned sheep and used similar techniques for the latest project.

Viragen said eggs had been used to make vaccines for more than 30 years. It said chicken proteins, unlike those from other modified animals, had very similar sugars to humans so patients were less likely to develop antibodies which neutralised the protein drugs' effects.

Friday, January 12, 2007

Bayer, Novartis near deal over Betaseron-paper





Fri Jan 12, 2007 12:02am ET

FRANKFURT, Jan 12 (Reuters) - Drugs and chemicals group Bayer (BAYG.DE: Quote, Profile, Research) and Swiss rival Novartis (NOVN.VX: Quote, Profile, Research) are closer to settling a legal wrangle in the United States over the production and marketing of Bayer's key Betaseron drug, a paper reported.

The companies have made a joint request to a California court to postpone a deadline set for next Tuesday so that they can continue with settlement talks, the Financial Times Deutschland said on Friday. Bayer stock rose almost 4 percent.

The firms' lawyers wrote in December that the trial should be postponed until Feb. 20 "to make it possible to conclude the settlement negotiations currently being carried out between the parties", the paper said.

The dispute is over rights relating to multiple sclerosis medication Betaseron, which is one of Bayer unit Schering's star performers. Schering said in November it was suing Novartis in connection with the drug.

Bayer was not immediately available to comment. Novartis declined to comment

Shares in Bayer were up 3.2 percent at 43.27 euros by 0954 GMT, making it the top gainer on the German DAX <.GDAXI> index.

Multiple sclerosis is most common cause of neurological disability in young adults in U.K.





Pain & Central Nervous System Week - Jan. 15, 2007

2007 JAN 15 - (NewsRx.com) -- Multiple sclerosis is the most common cause of neurological disability in young adults in the UK. Research and Markets has announced the addition of Espicom Business Intelligence's CNS Drug Discoveries: Multiple Sclerosis Chapter to their offering.

The incidence of multiple sclerosis varies throughout the world, although there is a significantly higher incidence of the disease found in the Northern Hemisphere.

It is variable in presentation and progression. Although there is no cure, there are many symptomatic treatments available. However, many patients do not respond to currently available products (30%) and the more chronic forms (secondary-progressive MS) are poorly treated with existing therapies.

The MS market is estimated to be worth U.S.$4.9 billion in 2006 with a growth rate of 8.9% year-on-year. It is the fifth largest segment of the CNS market and has attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma.

Sales growth will be driven by current drugs gaining broader indications, MS medicine being prescribed earlier in treatment in clinically-defined multiple sclerosis patients and the longer-term use of combination therapies as more classes of drug become available.

This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.

Drugmakers' `Arms Race' May Spur Biotechnology Deals





By Angela Zimm

Jan. 12 (Bloomberg) -- Vincent Aita of Kilkenny Capital Management says he picks biotechnology stocks on their potential as takeover targets. The strategy is paying off.

The number of biotech deals, including acquisitions and product alliances, rose 32 percent to 232 last year, according to data compiled by Bloomberg. At least four of Aita's holdings, including Serono SA and Kos Pharmaceuticals Inc., were bought by bigger drugmakers. Aita, who manages about $200 million in health stocks, is betting there will be even more transactions in 2007.

``There is an escalating arms race,'' Aita said in an interview at the JPMorgan Healthcare Conference this week in San Francisco. ``There are more deals to be had.''

Pfizer Inc., the world's largest pharmaceuticals maker, and Merck & Co. may buy biotech companies to make up for a scarcity of experimental medicines and expiring patents for best-selling products. On the shopping list are companies with experimental compounds as well as those with new drug-development science and technologies, investors at the conference said.

Last year the number of biotech deals in North America, including company acquisitions and joint ventures, increased from 175 in 2005, and the average premium rose to 33 percent from 23 percent, based on Bloomberg data.

More transactions and higher premiums are likely this year, according to analysts, investors and company executives interviewed this week at the San Francisco conference, the annual meeting where buyers and sellers gather to make deals. About 7,000 people packed hallways and conference rooms at the Westin St. Francis Hotel to hear presentations from 310 companies.

Upward Trend

``Premiums are going up,'' JPMorgan analyst Geoffrey Meacham said in an interview. ``You're seeing a lot of bidding wars.''

Driving the trend are big pharmaceutical companies with billions in cash that need new drugs to ensure growth. New York- based Pfizer may lose almost half of its $51 billion in 2005 sales as a result of competition from generic drugmakers to products with expiring patents. Pfizer, with $30 billion, has entered at least six research partnerships since November. Two transactions for which a value was disclosed totaled a combined $450 million.

Merck's Deals

Merck, the fourth-largest U.S. drugmaker, may lose $3 billion in sales this year from its top-selling Zocor cholesterol pill because of generic competition. It signed 35 transactions last year, including the $1.1 billion million purchase of San Francisco-based Sirna Therapeutics Inc., which is developing drugs based on blocking genes involved in disease.

Whitehouse Station, New Jersey-based Merck aims to become ``the best biotechnology company,'' Chief Executive Officer Richard Clark said in an interview at this week's meeting. Merck's biotech deals totaled $1.4 billion in 2006.

``It's science and technology and potential companies; we're looking at all ends of the spectrum,'' Clark said. ``Obviously, it's competitive.''

Eli Lilly & Co., which is offering $2.28 billion to buy its biotech partner Icos Corp., is spending $1.5 billion this decade on building its own biotechnology operations.

``The price of poker has definitely gone up,'' said John Lechleiter, Indianapolis-based Lilly's president and chief operating officer, at the conference. ``There are too few good assets and too many bidders.''

Amgen Inc., the world's biggest biotechnology company, and Biogen Idec Inc. also are considering acquisitions and alliances.

Biogen

Biogen since May has bought three companies with a combined value exceeding $270 million to reduce reliance on its biggest product, the multiple sclerosis treatment Avonex. Last week, the Cambridge, Massachusetts-based company agreed to pay as much as $120 million for closely held Syntonix Pharmaceuticals, adding experimental treatments for hemophilia.

Merck's shares rose 29 cents to $44.55 at 9:37 a.m. in New York Stock Exchange composite trading. Pfizer shares were unchanged and Lilly's shares increased 19 cents to $52.42. Amgen shares jumped 59 cents to $72.50 and shares of Biogen were up 6 cents or $50.50.

`Most Active'

The pace of acquisitions ``is the most active in our history,'' Biogen CEO James Mullen told investors in a presentation at the conference. There were 10 announced company acquisitions last year, up from 8 in 2005, JPMorgan analyst Meacham said in a Jan. 5 investment report

Premiums over the market price of traded shares also are rising. They ranged from 21 percent for Swiss drugmaker Actelion Ltd.'s purchase of Cotherix Inc., a U.S. biotechnology company, to 170 percent for AnorMed Inc., which Genzyme Corp. took over in a bidding war with rival Millennium Pharmaceuticals Inc.

``Last year saw the first hostile bid by a biotechnology company,'' in the Genzyme takeover of AnorMed, said Steven Burrill, CEO of Burrill & Co., a life-sciences investment adviser in San Francisco.

``Premiums are running 50 percent to 100 percent, which means the market is undervaluing the stocks,'' Burrill said.

Biotechnology companies raised $20 billion in partnership deals last year, up from $17 billion in 2005, according to Burrill.

Companies already aligned with bigger drugmakers through partnerships are likely takeover targets, said Kilkenny's Aita.

Amgen

Last year Amgen, purchased its partner, Abgenix Inc., to gain control of the cancer drug Vectibix. Genentech Inc., the world's No. 2 biotechnology company, agreed to buy its partner Tanox Inc. in November, gaining the asthma medication Xolair. The $919 million transaction was the first acquisition in Genentech's history.

Biotech companies in partnerships that may be takeover targets include Onyx Pharmaceuticals Inc., which co-markets the Nexavar kidney cancer drug with Bayer AG, and New River Pharmaceuticals Inc., which sold rights to its hyperactivity treatment to London-based Shire Plc, Aita said.

Others include BioMarin Pharmaceutical Inc., which shares a rare-disease drug with Genzyme, and Millennium, which co-markets its Velcade cancer drug with Johnson & Johnson.

``You don't often see biotechnology companies selling out of weakness,'' Aita said. ``Partnering and M&A have been the lifeblood of the industry. Consolidation isn't going away.''

To contact the reporter on this story: Angela Zimm in San Francisco azimm@bloomberg.net

Last Updated: January 12, 2007 09:50 EST

UK chimeric stem cell research in the balance





By Dr Matt Wilkinson

12/01/2007 - The UK’s Human Fertilisation and Embryology Authority (HFEA) has called for a public consultation into the use of animal eggs to create cloned hybrid or chimeric human embryos for laboratory-based disease research.

The HFEA has ruled that while it has the authority to license research into human-animal hybrid embryos and that while legislation doesn't prohibit it, it doesn't have enough evidence to grant licenses and so has called for a public consultation. The consultation will be completed by the autumn and forestalls the licensing decision about this controversial and potentially life-changing technology.
In a statement to the press, Angela McNab, HFEA chief executive, said: “The issues around hybrid and chimera research are unique and different from mainstream human embryo research. They have proved challenging but as the independent regulator we have a duty to judge this work under the current law.”

“After weighing up the scientific, legal and ethical issues presented to Wednesday's meeting, the authority decided that there needs to be a full and proper public debate and consultation as to whether, in principle, licences for these sorts of research could be granted.”

Dr Stephen Minger, Kings College London and Lyle Armstrong, Newcastle University, have both applied to the HFEA for licenses to carry out research into human-animal hybrid embryos also known as chimeric embryos.

The research would involve cloning human eggs inside the shell of rabbit or cow eggs from which the nucleus has been removed, a technique known as somatic cell nuclear transfer (SCNT). SCNT using human eggs is currently legal in the UK and the USA.

The resulting clones, which would be 99.5 per cent human, could be used as a source of embryonic stem cells, as well as models on which to study new therapies for devastating neurological disorders such as Alzheimer's and motor neuron disease.

The UK government had recently been accused of bowing to pressure from religious groups after ministers sought legislation to prohibit the experiments. The HFEA has shown that it is willing to listen to all arguments and feels it has the responsibility to allow scientists to present the evidence to the public and allow time for a proper debate.

Commenting on the decision, Armstrong said: “Overall, I think the HFEA announcement is a lot better than it could have been. They have not supported an outright ban of our work and moreover, the possibility of a further public consultation exercise gives us the opportunity to explain why the science is so very important for Britain and humanity in general.”

Minger said: “One good outcome is that the HFEA has not buckled under pressure from the government on this issue.”

Following the announcement, Aisling Burnand, chief executive of the UK's BioIndustry Association (BIA), commented: "The BIA is pleased that the HFEA's announcement does not support the proposed ban in the Government White Paper on research using hybrid embryos."

"There is widespread scientific and public support for this ground-breaking medical research into treatments for diseases such as multiple sclerosis, Parkinson's disease and motor neurone disease."

"Preventing the research would dash the hopes of millions of patients. It would also completely undermine the Government's support for stem cell research and its commitment to establishing the UK as a world-leading location for innovative scientific research."